Equities researchers at Leerink Swann assumed coverage on shares of Mirna Therapeutics, Inc. (NASDAQ:SYBX) in a research note issued on Tuesday. The brokerage set an “outperform” rating and a $25.00 price target on the biotechnology company’s stock. Leerink Swann’s price target suggests a potential upside of 33.48% from the stock’s current price.
Separately, ValuEngine lowered shares of Mirna Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company’s stock. Mirna Therapeutics has an average rating of “Hold” and an average price target of $15.15.
Shares of Mirna Therapeutics (NASDAQ:SYBX) opened at 18.73 on Tuesday. Mirna Therapeutics has a 12-month low of $7.84 and a 12-month high of $23.00. The firm’s market cap is $304.96 million. The company’s 50 day moving average price is $12.11 and its 200 day moving average price is $12.91.
TRADEMARK VIOLATION WARNING: “Mirna Therapeutics, Inc. (SYBX) Coverage Initiated by Analysts at Leerink Swann” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.chaffeybreeze.com/2017/09/19/mirna-therapeutics-inc-sybx-coverage-initiated-by-analysts-at-leerink-swann.html.
About Mirna Therapeutics
Synlogic, Inc, formerly Mirna Therapeutics, Inc, is engaged in the development of a novel class of living treatments, Synthetic Biotic medicines. The Company uses its proprietary Synthetic Biotic development platform. Its pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.